WARSAW, Ind., May 04, 2023 (GLOBE NEWSWIRE) -- OrthoPediatrics Corp. (“OrthoPediatrics” or the “Company”) (Nasdaq: KIDS) a company focused exclusively on advancing the field of pediatric orthopedics, today announced the launch of their new Power System for the RESPONSE™ Scoliosis portfolio. The RESPONSE Power System is a complete portfolio of instruments for tapping pedicles, inserting screws, and final tightening of set screws. RESPONSE Power is compatible with OrthoPediatrics’ entire suite of fusion implant systems, including RESPONSE 4.5/5.0and RESPONSE 5.5/6.0 fusion systems, and BandLoc – a sublaminar banding technology. This represents the company’s 49th system for pediatric orthopedic care.
Greg Odle, President of OrthoPediatrics’ Scoliosis business, commented, “Scoliosis procedures are physically demanding for surgeons, and can take a toll on their bodies over time. Our new RESPONSE Power System is designed to provide a more efficient workflow, easier screw insertion, and reduced effort required during final tightening of set screws.”
“The new Power System is a great complement to the RESPONSE Spine portfolio,” said Dr. Timothy Oswald, Pediatric Orthopedic Surgeon at Wellstar Pediatric Orthopedic Care in Atlanta. “Being able to efficiently and safely place and secure implants is critical in fusion procedures, and the new Power System instrumentation provides significant value over manual instrumentation to accomplish these steps. One important advantage is the reduced physical demand on surgeons, which may increase our longevity in the OR.”
About OrthoPediatrics Corp.
Founded in 2006, OrthoPediatrics is an orthopedic company focused exclusively on advancing the field of pediatric orthopedics. As such it has developed the most comprehensive product offering to the pediatric orthopedic market to improve the lives of children with orthopedic conditions. OrthoPediatrics currently markets 49 systems that serve three of the largest categories within the pediatric orthopedic market. This product offering spans trauma and deformity, scoliosis, and sports medicine/other procedures. OrthoPediatrics’ global sales organization is focused exclusively on pediatric orthopedics and distributes its products in the United States and over 70 countries outside the United States. For more information, please visit www.orthopediatrics.com.
Investor Contact
Philip Trip Taylor
Gilmartin Group
This email address is being protected from spambots. You need JavaScript enabled to view it.
415-937-5406
Last Trade: | US$22.49 |
Daily Change: | 0.11 0.49 |
Daily Volume: | 69,673 |
Market Cap: | US$544.710M |
November 26, 2024 November 06, 2024 August 05, 2024 August 05, 2024 |
Chimerix is on a mission to develop medicines that meaningfully improve and extend the lives of patients facing deadly diseases. The company is devoted to filling gaps in the treatment paradigm. Chimerix’s most advanced clinical-stage program is in development for H3 K27M-mutant glioma....
CLICK TO LEARN MOREImmix Biopharma is a clinical-stage biopharmaceutical company pioneering a novel class of CAR-T cell therapies and Tissue-Specific Therapeutics targeting oncology and immuno-dysregulated diseases with >75 patients treated to-date. Our lead cell therapy asset is NXC-201...
CLICK TO LEARN MOREEnd of content
No more pages to load
COPYRIGHT ©2023 HEALTH STOCKS HUB